[ad_1]
IRVING, Texas, March 28, 2019 / PRNewswire / – Caris Life Sciences®, A major innovator in the field of molecular sciences, focused on realizing the promise of precision medicine, announced today the release of new data in Cellular chemical biology which could offer a new treatment option for non-Hodgkin's lymphoma (NHL). The published results show for the first time the identification of a splenosomal complex on the surface of potentially interesting cancer cells as an antitumour drug target.
The paper, "The translocation of a spliceosomal cell surface complex induces alternative splicing events and lymphoma cell necrosis," confirms the identification of a spliceosomal molecular complex composed of proteins typically present in the nucleus or cytoplasm of cells and unexpectedly located on the surface. of the cancer cell.
The complex was discovered using a single-stranded DNA aptamer, C10.36, specific for NHL. The aptamer was discovered by employees of Caris Life Sciences, Günter Mayer and Michael Famulok, at the Life & Medical Sciences Institute of the University of Bonn. The identification of the target was carried out using the patented ADAPT Biotargeting System ™ system from Caris previously described by Domenyuk et al. in Scientific reports and Nature Communications.
The results show that when aptamer C10.36 binds to its target on the surface of the cell, the complex is transferred to the cell, resulting in global changes in the splicing of the cell. RNA ("splicing chaos") and necrotic cell death. This represents the first time that a spliceosomal complex is identified on the surface of the cell.
"To our knowledge, this study demonstrates that the C10.36 aptamer specifically recognizes a unique spatial arrangement of a large splenosomal complex on the surface of NHL cells," said Heather A. O Neill, Ph.D., principal investigator at Caris Life Sciences and co-lead author of the paper. "We believe that the erroneous location of the complex on the surface of the cell may play a role in the conduct and / or maintenance of the malignant state.For the first time, we have identified a spletosomal complex on the surface of cancerous cells that can be continued as a new drug target ".
"The ability of the aptamer to cause cell necrosis and the presence of the complex on different NHL cells open up two interesting avenues for basic and translational research.Our results motivate studies to unveil the function. of surface splenosomal complexes and its role in cancer, but also to study the potential of the aptamer as a therapeutic agent, "said Günter Mayer, Ph.D. Center Aptamer Research and Development, University of Bonn.
"This article further demonstrates the power of our patented ADAPT Biotargeting System ™, able to identify new drug targets for therapeutic and diagnostic applications," said David Spetzler, M.S., Ph.D., M.B.A., President and Scientific Director of Caris Life Sciences. "Our work with the University of Bonn is an excellent example of how our use of ADAPT can help researchers by identifying unique molecular targets for further understanding and exploring new approaches to cancer treatment. "
ADAPT Biotargeting System ™ is Caris' proprietary unbiased profiling platform that utilizes a vast library of synthetic molecules (aptamers) that bind to a wide range of biological targets and characterize complex biological systems in their state of being. origin, which allows them to profile biological samples. at the scale of systems.
The document was published in March 28 online number of Cellular chemical biology and is available online here and DOI: https://doi.org/10.1016/j.chembiol.2019.02.016.
About the life sciences Caris
Caris Life Sciences® is a leading innovator in molecular science, focused on realizing the promise of precision medicine through quality and innovation. The company's advanced molecular profiling product line evaluates DNA, RNA and proteins to reveal a molecular model that helps doctors and cancer patients make more accurate therapeutic decisions and custom. Caris is also advancing precision medicine with Next Generation Profiling ™, which combines its innovative service offerings, Caris Molecular Intelligence® and ADAPT Biotargeting System ™, with its dedicated badysis engine, artificial intelligence, DEAN ™, to badyze whole exome, whole transcriptome and complete cancer. proteome. This information, coupled with mature clinical outcomes across thousands of patients, provides unparalleled molecular solutions to patients, physicians, payers, and biopharmaceutical organizations. Headquarters at Irving, Texas, Caris Life Sciences offers services throughout the United States, Europe , Asia and other international markets. To learn more, visit www.CarisLifeSciences.com or follow us on Twitter (@CarisLS).
Contact & Media Company:
Srikant Ramaswami
Vice President, Communications Manager
[email protected]
+ 1-214-769-5510
SOURCE Caris Life Sciences
Related Links
http://www.carislifesciences.com
[ad_2]
Source link
